In-stent stenosis: pathology and implications for the development of drug eluting stents - Wikidata - awgldk - TriplyDB

In-stent stenosis: pathology and implications for the development of drug eluting stents

In-stent stenosis: pathology and implications for the development of drug eluting stents

http://www.wikidata.org/entity/Q24674571

about

Non thermal irreversible electroporation: novel technology for vascular smooth muscle cells ablation 'Miracle stents'--a future without restenosis Recent advances in drug eluting stents Sirolimus-eluting stents for treatment of in-stent restenosis: immediate and late results Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets.Impact of C-reactive protein on in-stent restenosis: a meta-analysis.Targeting PI3Kγ activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response.Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies.Comparison of reendothelialization and neointimal formation with stents coated with antibodies against endoglin and CD34 in a porcine model Lymphaticosclerosis: a new way of thinking about lymphatic vessel obstruction Early experiences and clinical implications of drug-eluting stents: part 1.In stent restenosis: bane of the stent era.Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes Intimal Thickening after Placement of a Neuroform Stent. Its Incidence and Relation to Angiographic Follow-up Results of Aneurysm Embolization Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting.Drug-eluting stents: from evidence to policy.A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease.Cypher versus Taxus: the stent war.BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease.Safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon following bare metal stent implantation in rabbit aorta abdominalis.Techniques in Vascular and Interventional Radiology Drug Delivery Technologies in the Superficial Femoral Artery The correlation between early complications of percutaneous coronary intervention and high sensitive C-reactive protein Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study.Chronic Caffeine Administration Attenuates Vascular Injury-Induced Neointimal Hyperplasia in Rats.Preclinical models of restenosis and their application in the evaluation of drug-eluting stent systems.Research and innovation in the development of everolimus for oncology.Surface chemical and physical modification in stent technology for the treatment of coronary artery disease.Coronary stents: historical development, current status and future directions.Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury.Stent-mediated gene and drug delivery for cardiovascular disease and cancer: A brief insight.Paclitaxel-eluting nanofiber-covered self-expanding nonvascular stent for palliative chemotherapy of gastrointestinal cancer and its related stenosis.Berberine suppresses in vitro migration of human aortic smooth muscle cells through the inhibitions of MMP-2/9, u-PA, AP-1, and NF-κB.The relation of aortic stiffness and in-stent restenosis in patients undergoing percutaneous coronary stenting.Berberine cooperates with adrenal androgen dehydroepiandrosterone sulfate to attenuate PDGF-induced proliferation of vascular smooth muscle cell A7r5 through Skp2 signaling pathway.Diagnosis and management challenges of in-stent restenosis in coronary arteries.A meta-analysis of clinical trials of paclitaxel- and sirolimus-eluting stents in patients with obstructive coronary artery disease.Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients.Critical Limb Ischemia: A Practical Up-To-Date Review.

P2860

Q21562470-0F4416D7-8E1D-4549-A5A5-1DEE55A56C20 Q24645049-EAEE1FDE-3DF2-4B40-AF3E-D2AB5717A8DA Q27025538-3AEAC580-ACF4-4497-A8E8-D3F8A11F84D7 Q28175715-16A06E9C-89A6-46D5-92E9-F98C428178CB Q28576577-EE33870D-0ACE-4779-9ED8-09DBB1186A90 Q33314508-54E7C948-1175-43B9-9452-A1DDB1923734 Q33693147-06AED156-B9BB-4F36-904F-796D8D28E361 Q34089207-80898C95-2E5E-40AB-9E30-379EFE1C8566 Q34432576-3F66B0E8-005A-4204-BCC8-FF8DDD9BB631 Q35535453-DEA9572B-BCF6-4C0E-9100-08B80902808C Q35602368-31BFE242-CF49-4100-B757-A051986225E9 Q35651217-B21D81B3-04E0-4FCE-8158-1784DE9B13CE Q35769824-AF951972-26B2-4B51-81DF-8FF2E8FAE59F Q35772244-ECD3ADE4-470C-4FB6-8B42-DAE6B3A6FD60 Q35937571-81F17E8E-DE4A-471A-B12D-53639D108CBE Q36241566-6FB41C8B-21A9-4566-8655-436539332173 Q36314909-5284132E-EB24-482B-B196-80B4AACD62E0 Q36488244-28DB217C-EE5A-4F2B-863B-278499332B83 Q36654328-3BDC7137-4E32-47F3-B12A-40BB95C5814C Q36728852-312DE15A-9F6D-4B1A-8F5F-1548FBFF4068 Q37044202-567E722C-345B-4F16-B9FE-467C4E227CBF Q37102287-037842BC-E35E-4159-AE94-DEC5243B8CAB Q37104135-0B0602C5-5E0B-48BA-BE0B-FC4A812D2088 Q37387376-D8215703-636E-4278-9D6E-99E82F916029 Q37406660-8F305D2D-0380-44F3-B82F-B4BE16DEB9B8 Q37676695-DB95E487-533E-495E-8493-ACE5351904CE Q38014589-61A0C579-6D4F-4B3C-A806-9A66A3544C8A Q38040738-96AA3511-2535-4ABE-8DAF-599454377519 Q38093501-702899F8-1A82-46D5-B420-EFC1EE2A6791 Q38105361-2189F20C-02E8-43C1-9282-C91CF5EFF687 Q38332355-035FFD3E-317E-40CC-954E-A61D15BA43BE Q38735846-CB6A9AF1-1449-4CCA-885A-6F7B4268196C Q38964790-A54E6122-1A35-4EC7-8518-63CF1972F077 Q39052677-D42B09DD-6654-498A-AFF8-426931F374A4 Q39438384-12C54AF1-022C-4451-9467-10A30B1F27A8 Q39550187-1E23AF32-EE9B-422C-B61A-DE6A0BE3908B Q41608247-552EFE2B-0B5A-43E5-BB6C-6B7957389416 Q42187564-9B32F962-9AE0-43C8-A195-58826104856B Q46701610-926A1FC4-DE11-4DDA-9FB7-37C77208D1CA Q47604696-921E1ED4-6DF2-4E4B-BF04-EA5DBDDA95DD

P2860

In-stent stenosis: pathology and implications for the development of drug eluting stents

http://www.wikidata.org/entity/Q24674571

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

In-stent stenosis: pathology and implications for the development of drug eluting stents

@ast

In-stent stenosis: pathology and implications for the development of drug eluting stents

@en

In-stent stenosis: pathology and implications for the development of drug eluting stents

@nl

type

label

In-stent stenosis: pathology and implications for the development of drug eluting stents

@ast

In-stent stenosis: pathology and implications for the development of drug eluting stents

@en

In-stent stenosis: pathology and implications for the development of drug eluting stents

@nl

prefLabel

In-stent stenosis: pathology and implications for the development of drug eluting stents

@ast

In-stent stenosis: pathology and implications for the development of drug eluting stents

@en

In-stent stenosis: pathology and implications for the development of drug eluting stents

@nl

P1433

Q24674571-2C3447D2-02AC-41D8-A89A-8528D9B4000B

P1476

Q24674571-DBA1B53F-1DBE-440E-AAAC-ECA6552C01B3

P2093

Q24674571-902F1A70-5BD9-4C45-B80E-550FC882408E

P2860

Q24674571-05A2AB83-65E5-4C9F-8219-E35E66ABD154

Q24674571-05E9BA9B-B2BF-4BC0-BE1A-540C4F31EC1C

Q24674571-3E3C66C3-A98D-4E3D-BDFE-A89D5F095EEC

Q24674571-4C151B03-A930-45DB-BCC0-100854B3E9DD

Q24674571-806E82B8-6D66-40BE-A93E-D33B39A62232

Q24674571-996C2D27-3D98-4D0C-9370-6D0CF0AEA529

Q24674571-AE023829-855F-4301-8ECC-2CD4C3228D5E

Q24674571-B689C2B2-7EBD-4898-AA81-ABF3D30B0AE6

Q24674571-D77B965A-BCA0-46FA-9479-555ECD22AB72

Q24674571-DF0F7926-3D72-4CCC-87E0-7076C81C9EBA

P304

Q24674571-C3E0541F-C76E-44EF-BC4E-AF9E43E1DB77

P31

Q24674571-2CF49A40-1D0A-426E-BBFD-0E2D9B529A2D

P356

Q24674571-411622C4-F5D7-45B0-B446-F3C5D217C98F

P407

Q24674571-B07DCB98-41A5-4DFD-BE05-A8CD75AF2930

P433

Q24674571-A8DBE650-4B4E-4BBF-8D81-A699B5FF0687

P478

Q24674571-1F40DD38-467A-4D34-BF39-2746E3049546

P577

Q24674571-92F79DE1-311E-4317-A184-612D9C32CED3

P5875

Q24674571-E037094E-D29B-4227-85F7-41D1FDD56379

P698

Q24674571-4FE0B9EE-BEDE-485A-A0EA-63048BEDC1A2

P921

Q24674571-99d1f30e-f6e6-4114-8769-61ae34ab8112

P932

Q24674571-1F6C2E84-4B04-40AE-8632-FAC0F6C7A35E

P356

P1433

P1476

In-stent stenosis: pathology and implications for the development of drug eluting stents

@en

P2093

Martin R Bennett

http://www.w3.org/2001/XMLSchema#string

P2860

Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization

Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy.

Rapamycin resistance tied to defective regulation of p27Kip1.

Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study.

Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model.

Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin.

Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model.

Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up.

Pathological analysis of local delivery of paclitaxel via a polymer-coated stent.

P304

218-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/HEART.89.2.218

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10950319

http://www.w3.org/2001/XMLSchema#string

P698

12527687

http://www.w3.org/2001/XMLSchema#string

P921

P932

1767562

http://www.w3.org/2001/XMLSchema#string